У Хайруллаев
Research Subjects
У Хайруллаев has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Guzal Mullabaeva
Республиканский Специализированный Научно-Практический Медицинский Центр Кардиологии
2 shared publications - И Шарипов
Республиканский специализированный кардиологический научно-практический центр
1 shared publication
Latest Publications
- Open Access
- 30 June 2025
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 2 (2) , 145-151
Систематический обзор хирургии клапанов сердца с непрерывной коронарной перфузией на работающем сердце у пациентов с низкой фракцией выброса левого желудочка.
Aim. Beating-heart continuous coronary perfusion (BHCCP) is an alternative to cardioplegic arrest in valve surgery, potentially reducing ischemic reperfusion injury, especially in high-risk patients with low left ventricular ejection fraction (LVEF). Materials and methods. A systematic review of prospective and observational studies was conducted, focusing on BHCCP versus cardioplegia in valve surgery, with emphasis on patients with LVEF <35%. Results. Studies (e.g., Matsumoto et al., 2002) showed no significant difference in mortality or major complications, but BHCCP reduced myocardial damage markers (e.g., Troponin I, CK-MB) by 20–40% compared to cardioplegia. Clinical outcomes remained comparable across groups. Conclusion. BHCCP is a safe alternative to cardioplegia, with potential benefits in myocardial protection, though high-quality randomized trials are needed to confirm clinical superiority.
- 30 June 2025
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 2 (2) , 145-151
Open AccessСистематический обзор хирургии клапанов сердца с непрерывной коронарной перфузией на работающем сердце у пациентов с низкой фракцией выброса левого желудочка.
Aim. Beating-heart continuous coronary perfusion (BHCCP) is an alternative to cardioplegic arrest in valve surgery, potentially reducing ischemic reperfusion injury, especially in high-risk patients with low left ventricular ejection fraction (LVEF). Materials and methods. A systematic review of prospective and observational studies was conducted, focusing on BHCCP versus cardioplegia in valve surgery, with emphasis on patients with LVEF <35%. Results. Studies (e.g., Matsumoto et al., 2002) showed no significant difference in mortality or major complications, but BHCCP reduced myocardial damage markers (e.g., Troponin I, CK-MB) by 20–40% compared to cardioplegia. Clinical outcomes remained comparable across groups. Conclusion. BHCCP is a safe alternative to cardioplegia, with potential benefits in myocardial protection, though high-quality randomized trials are needed to confirm clinical superiority.
- Open Access
- 30 March 2025
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 2 (1) , 4-10
Сравнение эффективности оригинальной и генерической формы клопидогреля у больных с ИБС
Background. To evaluate the antiaggregation activity and clinical tolerability of Areplex (75 mg, ADAMED, Poland) compared to Plavix (75 mg, Sanofi-Winthrop Industrie, France) in CAD patients. Materials and methods. A blinded, randomized, two-parallel-group study included 40 patients with stable angina (FC I-IV). Platelet aggregation was assessed using the AP 2110 analyzer (SOLAR) with ADP (5 µmol/L) and arachidonic acid (0.5 mg/mL) inducers after a 300 mg loading dose. Results. At 24 hours post-dose, both groups showed significant reductions in aggregation degree and rate (p0.05). Safety profiles were comparable, with no adverse events reported. Conclusion. Areplex demonstrated bioequivalence to Plavix, with good tolerability, supporting its use as an effective antiplatelet agent in CAD patients.
- 30 March 2025
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 2 (1) , 4-10
Open AccessСравнение эффективности оригинальной и генерической формы клопидогреля у больных с ИБС
Background. To evaluate the antiaggregation activity and clinical tolerability of Areplex (75 mg, ADAMED, Poland) compared to Plavix (75 mg, Sanofi-Winthrop Industrie, France) in CAD patients. Materials and methods. A blinded, randomized, two-parallel-group study included 40 patients with stable angina (FC I-IV). Platelet aggregation was assessed using the AP 2110 analyzer (SOLAR) with ADP (5 µmol/L) and arachidonic acid (0.5 mg/mL) inducers after a 300 mg loading dose. Results. At 24 hours post-dose, both groups showed significant reductions in aggregation degree and rate (p0.05). Safety profiles were comparable, with no adverse events reported. Conclusion. Areplex demonstrated bioequivalence to Plavix, with good tolerability, supporting its use as an effective antiplatelet agent in CAD patients.